RT Journal Article
SR Electronic
T1 Argentine Registry of neurological manifestations due to coronavirus-19 (COVID-19)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253558
DO 10.1101/2021.03.19.21253558
A1 Alessandro, Lucas
A1 Appiani, Franco
A1 Bendersky, Mariana
A1 Borrego Guerrero, Brenda
A1 Bruera, Guadalupe
A1 Cairola, Patricia
A1 Calandri, Ismael
A1 Cardozo Oliver, Juan Martín
A1 Clément, María Emilia
A1 Di Egidio, Marianna
A1 Di Pace, José Luis
A1 Diaconchuk, Melina
A1 Esliman, Celeste
A1 Esnaola y Rojas, Ma Martha
A1 Fernández Boccazzi, Julián
A1 Franco, Andrea Fabiana
A1 Gargiulo, Gisella
A1 Giardino, Daniela Laura
A1 Gómez, César
A1 Guevara, Ana Karina
A1 Gutierrez, Natalia
A1 Hryb, Javier
A1 Viviana, Ibarra
A1 Janota, Franco
A1 Laserna, Mabel
A1 Larcher, Luis Alfredo
A1 Leone, Fernando
A1 Luetic, Geraldine
A1 Medina, Claudia Andrea
A1 Menichini, María Laura
A1 Nieto, Gonzalo
A1 Páez, María Fernanda
A1 Peñalver, Francisco
A1 Perassolo, Mónica
A1 Persi, Gabriel
A1 Pestchanker, Claudia
A1 Porta, Oscar
A1 Rey, Roberto Daniel
A1 Rodríguez, Gabriel Eduardo
A1 Romano, Marina
A1 Rugiero, Marcelo
A1 Saidón, Patricia
A1 Sica, María Florencia
A1 Stankievich, Erica
A1 Tarulla, Adriana
A1 Zalazar, Guillermo
YR 2021
UL http://medrxiv.org/content/early/2021/03/24/2021.03.19.21253558.abstract
AB COVID-19 disease has spread around the world since December 2019. Neurological symptoms are part of its clinical spectrum.Objective To know the neurological manifestations in patients infected by COVID-19 in Argentina.Methods Multicenter study conducted in adults, from May 2020 to January 2021, with confirmed COVID-19 and neurological symptoms. Demographic variables, existence of systemic or neurological comorbidities, the form of onset of the infection, alteration in complementary studies and the degree of severity of neurological symptoms were recorded.Results 817 patients from all over the country were included, 52% male, mean age 38 years, most of them without comorbidities or previous neurological pathology. The first symptom of the infection was neurological in 56.2% of the cases, predominantly headache (69%), then anosmia / ageusia (66%). Myalgias (52%), allodynia / hyperalgesia (18%), and asthenia (6%) were also reported. 3.2% showed diffuse CNS involvement such as encephalopathy or seizures. 1.7% had cerebrovascular complications. Sleep disorders were observed in 3.2%. 6 patients were reported with Guillain Barré (GBS), peripheral neuropathy (3.4%), tongue paresthesia (0.6%), hearing loss (0.4%), plexopathy (0.3%). The severity of neurological symptoms was correlated with age and the existence of comorbidities.Conclusions Our results, similar to those of other countries, show two types of neurological symptoms associated with COVID-19: some potentially disabling or fatal such as GBS or encephalitis, and others less devastating, but more frequent such as headache or anosmia that demand increasingly long-term care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was evaluated and approved by the research ethics committees of each participating unit: -Instituto Argentino de Investigaciones Neurologicas -Hospital Ramos Mejia -Hospital Durand -Hospital Fernandez _Hospital Privado de la Comunidad _Hospital Universitario CEMIC -Hospital de San Juan -Hospital Italiano de Buenos Aires -Sanatorio Trinidad Mitre -Sanatorio Las Lomas -Instituto Milstein -Hospital Privado de Rosario -Instituto Max Planck -Hospital Enrique Vera Barros -Sanatorio Dr Julio Mendez -Hospital Muniz -Hospital Tornu -Hospital Pinero -Sanatorio Finochietto -Sanatorio del Norte -Centro medico Roca -Hospital Bernardino Rivadavia -Instituto de Neurociencias de RosarioAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred in the manuscript are available upon request